NovaBridge Biosciences (NBP) Interest & Investment Income (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Interest & Investment Income of $1.8 million for Q4 2025, down 18.43% year-over-year from $2.2 million in Q4 2024, and down 16.53% quarter-over-quarter from $2.1 million in Q3 2025.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Interest & Investment Income (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Interest & Investment Income for 5 consecutive years, with $1.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest & Investment Income fell 18.43% year-over-year to $1.8 million; the TTM figure through Dec 2025 stood at $7.6 million (up 1.67% YoY), while the FY2025 annual figure was $7.6 million, up 1.67% from the prior year.
- Interest & Investment Income slipped to $1.8 million in Q4 2025 per NBP's latest filing, from $2.1 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $2.9 million in Q2 2023 and bottomed at $709000.0 in Q1 2024.
- Historically, Interest & Investment Income has averaged $2.1 million across 3 years, with a median of $2.1 million in 2025.
- Annual changes were most pronounced in 2024 — Interest & Investment Income retreated 26.24% — and 2025, when it soared 164.03%.
- NovaBridge Biosciences' Interest & Investment Income stood at $2.3 million in 2023, then dropped by 4.69% to $2.2 million in 2024, then fell by 18.43% to $1.8 million in 2025.
- Business Quant data shows NBP's Interest & Investment Income at $1.8 million in Q4 2025, $2.1 million in Q3 2025, and $1.8 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 10.98 Mn |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.79 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Dec 31, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.45 Mn |
| Jun 30, 2024 | 2.13 Mn |
| Mar 31, 2024 | 709,000.00 |
| Dec 31, 2023 | 2.31 Mn |
| Sep 30, 2023 | 2.48 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Dec 31, 2020 | 840,475.66 |
| Sep 30, 2020 | -42,910.27 |
| Dec 31, 2019 | 1.10 Mn |
| Sep 30, 2019 | 1.43 Mn |